Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer

Evidence indicates that lung cancer development is a complex process that involves interactions between tumor cells, stromal fibroblasts, and immune cells. Tumor-infiltrating immune cells play a significant role in the promotion or inhibition of tumor growth. As an integral component of the tumor microenvironment, tumor-infiltrating B lymphocytes (TIBs) exist in all stages of cancer and play important roles in shaping tumor development. Here, we review recent clinical and preclinical studies that outline the role of TIBs in lung cancer development, assess their prognostic significance, and explore the potential benefit of B cell-based immunotherapy for lung cancer treatment.

[1]  N. L. Johnson,et al.  Multivariate Analysis , 1958, Nature.

[2]  A. Chapoval,et al.  Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. , 1998, Journal of immunology.

[3]  K. Schimrigk,et al.  Shift in the IgG subclass distribution in patients with lung cancer. , 1999, Lung cancer.

[4]  Y. Soini,et al.  Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. , 1999, Lung cancer.

[5]  Y. Soini,et al.  A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  M. Edwardes,et al.  Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. , 2001, Canadian journal of surgery. Journal canadien de chirurgie.

[7]  J. Becker,et al.  Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. , 2001, Immunity.

[8]  K. Sugio,et al.  Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer. , 2002, Cancer research.

[9]  N. Martinet,et al.  Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. , 2002, The Journal of laboratory and clinical medicine.

[10]  T. Griffith,et al.  Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation1 , 2004, The Journal of Immunology.

[11]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[12]  R. Newberry,et al.  Adaptive Immune Responses Are Dispensable for Isolated Lymphoid Follicle Formation: Antigen-Naive, Lymphotoxin-Sufficient B Lymphocytes Drive the Formation of Mature Isolated Lymphoid Follicles 1 , 2005, The Journal of Immunology.

[13]  AID in somatic hypermutation and class switch recombination. , 2006, Current opinion in immunology.

[14]  K. Sugio,et al.  Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth. , 2006, Anticancer research.

[15]  J. Becker,et al.  Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue , 2007, Cancer Immunology, Immunotherapy.

[16]  K. Sugio,et al.  Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice. , 2007, Cancer research.

[17]  T. Dønnem,et al.  Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[18]  E. Tartour,et al.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Kaiser,et al.  B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models , 2008, Journal of immunotherapy.

[20]  J. Weiss,et al.  Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses. , 2008, Cancer immunity.

[21]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[22]  S. Lira,et al.  CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles , 2009, Mucosal Immunology.

[23]  A. Chang,et al.  In Vivo Sensitized and In Vitro Activated B Cells Mediate Tumor Regression in Cancer Adoptive Immunotherapy1 , 2009, The Journal of Immunology.

[24]  Baohui Xu,et al.  Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung , 2009, Respiratory research.

[25]  T. Dønnem,et al.  The prognostic value of intraepithelial and stromal CD3‐, CD117‐ and CD138‐positive cells in non‐small cell lung carcinoma , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[26]  Luigi Naldini,et al.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis. , 2010, Cancer cell.

[27]  R. Wersto,et al.  Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. , 2011, Cancer research.

[28]  P. Validire,et al.  Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. , 2011, Cancer research.

[29]  C. Sautès-Fridman,et al.  Tumor microenvironment is multifaceted , 2011, Cancer and Metastasis Reviews.

[30]  I. Adcock,et al.  B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. , 2011, American journal of respiratory and critical care medicine.

[31]  R. Bentley,et al.  The Association of Intratumoral Germinal Centers with Early-Stage Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  H. Hammad,et al.  Tertiary lymphoid organs in infection and autoimmunity , 2012, Trends in Immunology.

[33]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[34]  L. Holmberg,et al.  A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors , 2012, Clinical Cancer Research.

[35]  C. Mauri,et al.  Immune regulatory function of B cells. , 2012, Annual review of immunology.

[36]  F. Balkwill,et al.  B regulatory cells in cancer. , 2013, Trends in immunology.

[37]  R. Kreienberg,et al.  Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. , 2013, Cancer research.

[38]  S. Qiu,et al.  Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[39]  L. Holmberg,et al.  The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. , 2013, Cancer letters.

[40]  Hua Yu,et al.  Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer , 2013, PloS one.

[41]  T. Dønnem,et al.  CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. , 2013, Lung cancer.

[42]  S. Zakynthinos,et al.  CXCL13 production in B cells via Toll-like receptor/lymphotoxin receptor signaling is involved in lymphoid neogenesis in chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[43]  K. Becker,et al.  Cancer-Produced Metabolites of 5-Lipoxygenase Induce Tumor-Evoked Regulatory B Cells via Peroxisome Proliferator–Activated Receptor α , 2013, The Journal of Immunology.

[44]  F. Schuetz,et al.  B cell-regulated immune responses in tumor models and cancer patients , 2013, Oncoimmunology.

[45]  T. Bekaii-Saab,et al.  Peptide Vaccines and Peptidomimetics of EGFR (HER-1) Ligand Binding Domain Inhibit Cancer Cell Growth In Vitro and In Vivo , 2013, The Journal of Immunology.

[46]  R. de Cabo,et al.  Inhibition of Breast Cancer Metastasis by Resveratrol-Mediated Inactivation of Tumor-Evoked Regulatory B Cells , 2013, The Journal of Immunology.

[47]  Chi‐Huey Wong,et al.  Immunization of fucose-containing polysaccharides from Reishi mushroom induces antibodies to tumor-associated Globo H-series epitopes , 2013, Proceedings of the National Academy of Sciences.

[48]  D. Mount,et al.  Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma , 2014, BMC Medical Genomics.

[49]  M. Merino,et al.  Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. , 2013, Cancer research.

[50]  A. Yoshizawa,et al.  Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. , 2013, Human pathology.

[51]  Hua Yu,et al.  B Cells Promote Tumor Progression via STAT3 Regulated-Angiogenesis , 2013, PloS one.

[52]  C. Sima,et al.  Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  L. Coussens,et al.  B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. , 2014, Cancer cell.

[54]  Simon A. Jones,et al.  Ectopic lymphoid-like structures in infection, cancer and autoimmunity , 2014, Nature Reviews Immunology.

[55]  P. Validire,et al.  Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. , 2014, American journal of respiratory and critical care medicine.

[56]  F. Marincola,et al.  Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer , 2014, Journal of Translational Medicine.

[57]  A. Gómez,et al.  A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer , 2015, Clinical and Translational Oncology.

[58]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in cancer and beyond. , 2014, Trends in immunology.

[59]  K. Silina,et al.  Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue? , 2014, Cancer Immunology, Immunotherapy.

[60]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[61]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[62]  Z. Wang,et al.  Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. , 2015, Cancer letters.

[63]  Christopher J. Kane,et al.  Immunosuppressive plasma cells impede T cell-dependent immunogenic chemotherapy , 2015, Nature.

[64]  R. Herbst,et al.  Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.

[65]  P. Validire,et al.  A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality , 2015, Oncoimmunology.

[66]  Guang-Biao Zhou,et al.  The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution , 2015, eLife.

[67]  H. Liao,et al.  Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery , 2016, Cancer Immunology, Immunotherapy.

[68]  J. Rosenblatt,et al.  Regulatory B cells in anti-tumor immunity. , 2015, International immunology.

[69]  Fumito Ito,et al.  Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL‐10 , 2015, European journal of immunology.

[70]  M. Merad,et al.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. , 2015, American journal of respiratory and critical care medicine.

[71]  W. Ni,et al.  Protective Effects of Total Glucosides of Paeony on N-nitrosodiethylamine-induced Hepatocellular Carcinoma in Rats via Down-regulation of Regulatory B Cells , 2015, Immunological investigations.

[72]  G. Trinchieri,et al.  Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. , 2015, Cancer research.

[73]  Jochen Wilhelm,et al.  Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma , 2015, PloS one.

[74]  H. Asamura,et al.  Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  S. Lam,et al.  Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis , 2016, Molecular Cancer.

[76]  Hua Yu,et al.  CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. , 2016, Immunity.

[77]  J. Rosenblatt,et al.  B cell regulation of the anti-tumor response and role in carcinogenesis , 2016, Journal of Immunotherapy for Cancer.

[78]  C. Sautès-Fridman,et al.  Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention , 2016, Front. Immunol..

[79]  Hisao Asamura,et al.  Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator , 2016, Cancer Immunology Research.

[80]  Å. Helland,et al.  Rituximab efficiently depletes B cells in lung tumors and normal lung tissue , 2016, F1000Research.

[81]  Yiyan Liu,et al.  Aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in Non Small Cell Lung Carcinoma patients. , 2016, Human immunology.

[82]  A. Jemal,et al.  Lung Cancer Statistics. , 2016, Advances in experimental medicine and biology.

[83]  F. Ruiz-Cabello,et al.  Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer , 2016, Oncotarget.

[84]  Gwénaël Le Teuff,et al.  Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  C. Paweletz,et al.  Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. , 2016, JCI insight.

[86]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[87]  W. Cooper,et al.  The Role of Tumor‐Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[88]  C. Perou,et al.  Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. , 2016, Journal of the National Cancer Institute.

[89]  C. Pucillo,et al.  Message in a bottle from the tumor microenvironment: tumor-educated DCs instruct B cells to participate in immunosuppression , 2017, Cellular &Molecular Immunology.

[90]  C. Jamin,et al.  Influence of drug molecules on regulatory B cells. , 2017, Clinical immunology.

[91]  S. Woo,et al.  Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner , 2017, Cellular & Molecular Immunology.

[92]  Kristina M. Ilieva,et al.  B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment , 2017, Oncoimmunology.

[93]  M. McCarter,et al.  Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non–Small Cell Lung Cancer Patients , 2017, Cancer Immunology Research.

[94]  J. Madrigal,et al.  B cell regulation in cancer and anti-tumor immunity , 2017, Cellular &Molecular Immunology.

[95]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[96]  C. Perou,et al.  Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[97]  P. Adusumilli,et al.  CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. , 2017, Translational research : the journal of laboratory and clinical medicine.